Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 3
Locations
Israel
Study Type
Interventional
Intervention
sitagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion criteria:
- Patient has T2DM diagnosed within the past 5 years
- Patient is >18 and <65 years of age
- Patient is not pregnant, breast feeding and unlikely to conceive
- Patient understands the study procedures, and agrees to participate in the study by giving written informed consent
Patient meets one of the following criteria:
- Patient is currently not on an AHA and has a Visit 1 HbA1c ≥6.5% and ≤10%. OR
- Patient is currently on AHA monotherapy or low dose (i.e. ≤50% maximum labeled dose of each agent) oral combination therapy and has a Screening/Visit 1 HbA1c ≥6.5% and ≤9.5%.
- At visit 2, patient has a HbA1c of ≥6.5% and ≤10%
Exclusion Criteria:
- Patient has type 1 diabetes mellitus
- Patient required insulin therapy within 12 weeks of Visit 1. Note: patients who received a brief period of insulin treatment (e.g., several days during a hospitalization) and who are no longer requiring insulin treatment may participate
- Patient is currently or within 12 weeks of Visit 1 taking a TZD agent as monotherapy or in combination
- Patient is currently or within 12 weeks of Visit 1 taking Byetta.
- Patient is on corticosteroids
- Patient has a history of malignancy ≤5 years prior to signing informed consent, or >5 years without documentation of remission/cure Exception: Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Melanoma, leukemia, lymphoma and myeloproliferative disorders of any duration are excluded -Patient is on chemotherapy
- Patient received another investigational drug in the last 12 weeks.
- Patients with concomitant liver disease and or AST > 3 fold upper limit of normal
- Patients with kidney disease or CR>1.4 mg/dl
- Patients with anemia ( Hb <11 gr in male 10 gr in female)
- Patient with active vascular disease (coronary, peripheral or cerebrovascular)
- Patient has poorly controlled hypertension defined as systolic blood pressure >160 mm Hg or diastolic >95 mm Hg
- Proliferative retinopathy
Sites / Locations
- Sheba_Medical_Center
Outcomes
Primary Outcome Measures
FPG,
HbA1c,
β-cell Function Parameters(Φs, Φd, Φb, Φ, Φob, T), Insulin Secretion Rate (determined from C-peptide deconvolution), 1st and 2nd phase insulin secretion, Insulin response after arginine injection, Insulin sensitivity index, glucose, insulin,
C-peptide total and incremental area under the curve.
Secondary Outcome Measures
Full Information
NCT ID
NCT00425490
First Posted
January 22, 2007
Last Updated
September 22, 2009
Sponsor
Sheba Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00425490
Brief Title
Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus
Official Title
Phase III Study on the Effect of Sitagliptin on Maximal Beta Cell Stimulation
Study Type
Interventional
2. Study Status
Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Sheba Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study is designed to investigate the effect of 18 weeks treatment with Sitagliptin 100 mg/day on the insulin secretion capacity of beta cells.
Patients who meet the study enrollment criteria will undergo 2 experiments (see description below); a graded hyperglycemic technique and a meal test, prior to randomization and after a 12-wk double-blind study period. The treatment effect will shed light on the magnitude of the beta cell capacity to increase its mass and function.
Detailed Description
Study design and duration: This will be an Israeli three center study. Study drug: Sitagliptin 100 mg. The study will be a double blind, randomized two arms parallel group study. The duration of the study will be up to 18 weeks (with 8 visits) for each patient. This will include: a screening period of up to 4 weeks (Visit 1 to visit 2), a 2 week single blind, placebo run-in period (visit 2 to visit 4), and a 12 week placebo controlled, double blind treatment period (visit 4 to visit 8).
Patients with T2DM who have not been treated with an AHA, or who are on AHA monotherapy or low dose oral combination therapy (low dose defined as ≤50% of the maximum labeled dose of each agent), may participate if they meet all enrollment criteria. Patients eligible to be randomized will have a HbA1c ³6.5% and £10% .
Patients who meet the study enrollment criteria will undergo 2 experiments (see description below); a graded hyperglycemic technique and a meal test, prior to randomization (Visit 3 and 4). These experiments will be will be completed after a 12-hour overnight fast. The 2 experiments will be repeated at the conclusion of the 12-wk double-blind study period (Visits 7 and 8).
Efficacy measurements: (1) Glycemic control : FPG, HbA1c, β-cell Function Parameters(Φs, Φd, Φb, Φ, Φob, T), Insulin Secretion Rate (determined from C-peptide deconvolution), 1st and 2nd phase insulin secretion, Insulin response after arginine injection, Insulin sensitivity index, glucose, insulin, C-peptide total and incremental area under the curve.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
sitagliptin
Primary Outcome Measure Information:
Title
FPG,
Title
HbA1c,
Title
β-cell Function Parameters(Φs, Φd, Φb, Φ, Φob, T), Insulin Secretion Rate (determined from C-peptide deconvolution), 1st and 2nd phase insulin secretion, Insulin response after arginine injection, Insulin sensitivity index, glucose, insulin,
Title
C-peptide total and incremental area under the curve.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patient has T2DM diagnosed within the past 5 years
Patient is >18 and <65 years of age
Patient is not pregnant, breast feeding and unlikely to conceive
Patient understands the study procedures, and agrees to participate in the study by giving written informed consent
Patient meets one of the following criteria:
Patient is currently not on an AHA and has a Visit 1 HbA1c ≥6.5% and ≤10%. OR
Patient is currently on AHA monotherapy or low dose (i.e. ≤50% maximum labeled dose of each agent) oral combination therapy and has a Screening/Visit 1 HbA1c ≥6.5% and ≤9.5%.
At visit 2, patient has a HbA1c of ≥6.5% and ≤10%
Exclusion Criteria:
Patient has type 1 diabetes mellitus
Patient required insulin therapy within 12 weeks of Visit 1. Note: patients who received a brief period of insulin treatment (e.g., several days during a hospitalization) and who are no longer requiring insulin treatment may participate
Patient is currently or within 12 weeks of Visit 1 taking a TZD agent as monotherapy or in combination
Patient is currently or within 12 weeks of Visit 1 taking Byetta.
Patient is on corticosteroids
Patient has a history of malignancy ≤5 years prior to signing informed consent, or >5 years without documentation of remission/cure Exception: Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Melanoma, leukemia, lymphoma and myeloproliferative disorders of any duration are excluded -Patient is on chemotherapy
Patient received another investigational drug in the last 12 weeks.
Patients with concomitant liver disease and or AST > 3 fold upper limit of normal
Patients with kidney disease or CR>1.4 mg/dl
Patients with anemia ( Hb <11 gr in male 10 gr in female)
Patient with active vascular disease (coronary, peripheral or cerebrovascular)
Patient has poorly controlled hypertension defined as systolic blood pressure >160 mm Hg or diastolic >95 mm Hg
Proliferative retinopathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ohad Cohen, MD
Organizational Affiliation
Sheba Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheba_Medical_Center
City
Tel Hashomer
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus
We'll reach out to this number within 24 hrs